RE: SRA737 Trial Results27 Jun 2022 17:01
because on Fri 24th June 2022 WP'' breaking news
GSK, listed in London, said yesterday it would focus on malaria, tuberculosis and HIV, as well as the 20 tropical diseases that traditionally receive limited research funding. These neglected tropical diseases, or NTDs, which include leprosy, dengue, rabies and scabies, affect more than 1.7 billion people.
The FTSE 100 group, which is based in West London and employs about 94,000 people, will also look at resistance to antibiotics.
The announcement was made at a conference yesterday on Malaria and Neglected Tropical Diseases in Rwanda’s capital city, Kigali, bringing together world leaders, businesses and academics to discuss how to tackle these illnesses.
that's why i think plugging SRA737 all day is giving prospective investors false hope
that GSK will tell us something on progress of this valuable asset before they have a chance to
get it into the lab and have a look what Combo works with it best,
and certainly not before the full takeover of Sierra and tie up of all lose end, is announce..
at some point in July DYOR, and as the news above said, GSK is going to spend it's
time on these new project it is spending £1b on, I'm speculating if they are going to have any time
for 737 yet, or if they will tell us anything at all during development.. that's my concern
in the meantime all we have to look forward to is the imminent CTA to get 1801 100% owned
with no baggage, into the clinic at some point in H2 which is now''
and if they did bring out a paper from 2016 in March 22 it's too late now
as sierra should have told us in March?? but as usual they hide it away..
anyway Come on Sareum...
Sign In
Follow the stocks
